DrChrono
Winter 2011AcquiredThe essential platform for modern medical practices and patients.
Pressure-test this opportunity
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
The essential platform for modern medical practices and patients.
Turn this teardown into a decision-ready prompt for ChatGPT, Claude, or your agent.
If you only have a few minutes to spare, here’s what investors, operators, and founders should know about DrChrono (W11).
DrChrono saw the iPad as a clinician's clipboard before mobile electronic health records became obvious. Founded in 2009 by Michael Nusimow and Daniel Kivatinos, the Winter 2011 YC company expanded from a native iPad EHR into scheduling, intake, telehealth, billing, payments, revenue-cycle management, patient access, and an integration platform.[1]
This was not a shutdown. EverCommerce acquired 100% of DrChrono in November 2021 for $181.9 million and made it an anchor of EverHealth.[2] The strategic mechanism was vertical-suite expansion: DrChrono owned clinical and administrative workflow for independent practices; EverCommerce could attach payments, patient engagement, and adjacent services to the same customers. DrChrono remains an operating brand.
Nusimow and Kivatinos founded DrChrono in 2009 and joined YC's Winter 2011 batch.[1] Their early product began with a physical observation: clinicians needed records in the exam room without turning the encounter into desktop data entry.
“Doctors are beginning to adopt iPads and use them as clipboards,” Nusimow said in 2012. He explained the interaction problem more directly: “They don’t want to be distracted by typing on a computer when talking to patients.”[3]
The iPad supplied a credible new interface. A clinician could carry the record, show information, capture notes, and maintain eye contact. DrChrono's thesis was not merely that medical records should move to the cloud. It was that clinical software should fit the encounter.
The company raised $2.8 million in 2012 after an earlier $1.3 million round involving YC, Paul Buchheit, 500 Startups, and others.[3] That capital helped turn a mobile chart into a practice operating system.
The 2012 iPad product supported appointment scheduling, audio dictation, photographs, prescriptions, reminders, clinical notes, lab results, and electronic records.[4] It placed the core encounter workflow on a device clinicians could carry.
DrChrono then expanded across the independent-practice stack: EHR, practice management, scheduling, patient intake, telehealth, billing, revenue-cycle management, payments, and patient access.[7] The product followed a patient from booking through documentation, claims, payment, and follow-up.
An API and marketplace allowed healthcare developers to customize workflows and connect adjacent applications.[7] Named integrations included CoverMyMeds for prior authorization, DeepScribe for clinical notes, and IntelliH for remote monitoring.[6]
The breadth created switching cost and strategic value. It also placed DrChrono under HIPAA, ONC certification and interoperability rules, prescribing requirements, claims compliance, state telehealth rules, and third-party security obligations.[1]
DrChrono served independent physician practices across specialties. These customers needed clinical records and administrative tools without the implementation footprint of hospital software.
No audited market-size, revenue, margin, or retention data was observed. At the 2012 financing, DrChrono reported 15,000 registered providers and 400,000 patients.[4] Before acquisition, EverCommerce said the company served more than 4,600 practices and 13,000 providers.[7] The measures come from different dates and definitions and should not be combined.
DrChrono competed with independent-practice EHRs, practice-management tools, billing companies, patient-engagement products, and larger healthcare suites. Its mobile-first origin and integrated administrative stack distinguished it.
Read the complete post-mortem, the rebuild playbook, and the exact reasons DrChrono is still worth studying now.